Claudia Bartels

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11908924/publications.pdf

Version: 2024-02-01

430874 2,334 30 18 citations h-index papers

g-index 30 30 30 4064 docs citations times ranked citing authors all docs

552781

26

#	Article	IF	CITATIONS
1	Relevance of Subjective Cognitive Decline in Older Adults with a First-Degree Family History of Alzheimer's Disease. Journal of Alzheimer's Disease, 2022, 87, 545-555.	2.6	5
2	Cerebrospinal Fluid Total Tau Protein Correlates With Longitudinal, Progressing Cognitive Dysfunction in Anti-Neural Autoantibody-Associated Dementia and Alzheimer's Dementia: A Case–Control Study. Frontiers in Immunology, 2022, 13, 837376.	4.8	7
3	The BDNFVal66Met SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimer's disease. Molecular Psychiatry, 2021, 26, 614-628.	7.9	61
4	Association between composite scores of domain-specific cognitive functions and regional patterns of atrophy and functional connectivity in the Alzheimer's disease spectrum. Neurolmage: Clinical, 2021, 29, 102533.	2.7	15
5	Case Report: Semantic Variant of Primary Progressive Aphasia Associated With Anti-Glial Fibrillary Acid Protein Autoantibodies. Frontiers in Immunology, 2021, 12, 760021.	4.8	1
6	Figural Memory Impairment in Conjunction With Neuropsychiatric Symptoms in IgLON5 Antibody-Associated Autoimmune Encephalitis. Frontiers in Psychiatry, 2020, 11, 576.	2.6	15
7	Use of Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Risk in Mild Cognitive Impairment and Subjective Cognitive Decline in Routine Clinical Care in Germany. Journal of Alzheimer's Disease, 2020, 78, 1137-1148.	2.6	5
8	Minor neuropsychological deficits in patients with subjective cognitive decline. Neurology, 2020, 95, e1134-e1143.	1.1	58
9	Impaired empathy but no theory of mind deficits in adult attention deficit hyperactivity disorder. Brain and Behavior, 2019, 9, e01401.	2.2	21
10	Left frontal hub connectivity delays cognitive impairment in autosomal-dominant and sporadic Alzheimer's disease. Brain, 2018, 141, 1186-1200.	7.6	83
11	Prediction and Early Detection of Alzheimer's Dementia: Professional Disclosure Practices and Ethical Attitudes. Journal of Alzheimer's Disease, 2018, 62, 145-155.	2.6	29
12	How to pursue EPO in MS. Multiple Sclerosis Journal, 2018, 24, 1139-1140.	3.0	0
13	Impact of SSRI Therapy on Risk of Conversion From Mild Cognitive Impairment to Alzheimer's Dementia in Individuals With Previous Depression. American Journal of Psychiatry, 2018, 175, 232-241.	7.2	133
14	Effectiveness and cost-effectiveness of an integrated care program for schizophrenia: an analysis of routine data. European Archives of Psychiatry and Clinical Neuroscience, 2018, 268, 611-619.	3.2	1
15	Diagnostic Accuracy of Diffusion Tensor Imaging in Amyotrophic Lateral Sclerosis. Academic Radiology, 2013, 20, 1099-1106.	2.5	70
16	Response to Letter by Dame. Stroke, 2010, 41, .	2.0	0
17	Practice effects in healthy adults: A longitudinal study on frequent repetitive cognitive testing. BMC Neuroscience, 2010, 11, 118.	1.9	290
18	Recombinant Human Erythropoietin: Novel Approach to Neuroprotection and Neuroregeneration in Schizophrenia., 2010,, 397-415.		0

#	Article	IF	Citations
19	Recombinant Human Erythropoietin in the Treatment of Acute Ischemic Stroke. Stroke, 2009, 40, e647-56.	2.0	509
20	Therapeutic Potential of Erythropoietin and its Structural or Functional Variants in the Nervous System. Neurotherapeutics, 2009, 6, 108-127.	4.4	200
21	Callosal dysfunction in amyotrophic lateral sclerosis correlates with diffusion tensor imaging of the central motor system. Neuromuscular Disorders, 2008, 18, 398-407.	0.6	44
22	Development of an outcome prediction measure for alcoholism therapy by multimodal monitoring of treatment processes. Journal of Psychiatric Research, 2008, 43, 30-47.	3.1	10
23	Recombinant Human Erythropoietin in the Treatment of Human Brain Disease: Focus on Cognition. , 2008, 18, 146-153.		41
24	Review: Recombinant human erythropoietin: novel strategies for neuroprotective/neuroregenerative treatment of multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2008, 1, 193-206.	3.5	35
25	The influence of personality factors on disease progression and healthâ€related quality of life in people with ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2008, 9, 99-107.	2.1	23
26	Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis. Brain, 2007, 130, 2577-2588.	7.6	218
27	Personality Disorder and Chronicity of Addiction as Independent OutcomePredictors in Alcoholism Treatment. Psychiatric Services, 2006, 57, 708-712.	2.0	48
28	Follow-up of 180 Alcoholic Patients for up to 7 Years After Outpatient Treatment: Impact of Alcohol Deterrents on Outcome. Alcoholism: Clinical and Experimental Research, 2006, 30, 86-95.	2.4	96
29	Reduced oxidative damage in ALS by highâ€dose enteral melatonin treatment. Journal of Pineal Research, 2006, 41, 313-323.	7.4	253
30	RECOVERY OF HIPPOCAMPUS-RELATED FUNCTIONS IN CHRONIC ALCOHOLICS DURING MONITORED LONG-TERM ABSTINENCE. Alcohol and Alcoholism, 2006, 42, 92-102.	1.6	63